NCT01378091 - Study of Lenalidomide and Docetaxel in Subjects With Androgen Independent Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2005

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions

Prostate Cancer

Interventions

DRUG

Lenalidomide

"Supplied as 5 mg and 25 mg capsules.~The lenalidomide dose levels to be studied include 10, 15, 20, 25, 30, 35 and 40 mg/day."

DRUG

Docetaxel

"Docetaxel is an anti-cancer (antineoplastic or cytotoxic) chemotherapy drug.~Doses of docetaxel to be studied include 60 and 75 mg/m2 once every three weeks."

DRUG

Prednisone

"Prednisone is a synthetic corticosteroid drug that is particularly effective as an immunosuppressant drug.~5 mg BID daily."

Trial Locations (2)

10032

Columbia University Medical Center, New York

10065

Cornell Weill Medical Center, New York